StockData
Natera, Inc. logo

Natera, Inc.

NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30206% above fair value
$378.92−35.38 (-8.54%)

Close on Nov 2, 2026Market cap $54.62BP/E –Yield –

Natera Other Licensing & Services Revenue [legacy through Q1 by Year

Other Licensing & Services Revenue ($M) [legacy through Q1 2020] ($M)

Natera Other Licensing & Services Revenue [legacy through Q1: $11.0M in FY2019, up 65.1% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2019
11.0
Period ended Dec 31, 2019
Change on a year earlier
+65.1%
6.65 in FY2018
History
3 years
Since FY2017
Sources
1
Form 10-K (2020-03-02)

Where the FY2019 figure comes from

Source: Form 10-K (2020-03-02) ↗

Reported in Form 10-K/10-Q Note — Disaggregated Licensing Revenue (2017–2020Q1).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Licensing & Services Revenue ($M) [legacy through Q1 2020] ($M)Year on yearSource
FY2019Dec 31, 201911.0+65.1%Form 10-K (2020-03-02) ↗
FY2018Dec 31, 20186.65+310.5%Form 10-K (2020-03-02) ↗
FY2017Dec 31, 20171.62–Form 10-K (2020-03-02) ↗

Cite this data

StockData. (2026). Natera Other Licensing & Services Revenue [legacy through Q1 ($M), annual FY2017–FY2019 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/rev-legacy-other-licensing

See every metric in the Natera KPI table. Data updated Nov 2, 2026.